Microvention-Terumo
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Microvention-Terumo sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Microvention-Terumo: 9 sponsored US clinical trials, 1 recruiting.
Microvention-Terumo sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arteriovenous Dural Fistula, with 1 trials.
Top-decile sponsor footprint
Microvention-Terumo ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
NCT05409989
Ruptured Aneurysms Treated With Hydrogel Coils
NCT03252314
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
NCT04451525
PHIL in the Treatment of Intracranial dAVF.
NCT03467542
The WEB-IT Clinical Study
NCT02191618
Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)
NCT01793792
Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms
NCT01801007
Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device
NCT01541254
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
What is open in the Microvention-Terumo pipeline
1 recruiting of 9 indexed (11% open); 6 completed (67%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Arteriovenous Dural Fistula (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Microvention-Terumo: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Microvention-Terumo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this Microvention-Terumo page
9 registered trials is a research-attention snapshot, not an endorsement of Microvention-Terumo or any single study.
- 1 of Microvention-Terumo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Arteriovenous Dural Fistula is the condition Microvention-Terumo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arteriovenous Dural Fistula trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Microvention-Terumo pipeline card: 9 registered trials from official public datasets.Report a data error.